Budoprutug Study: This study looks at how safe and tolerable the drug budoprutug is for people with a kidney condition called Primary Membranous Nephropathy (PMN). Budoprutug is a special medicine called a monoclonal antibody, which helps the body’s immune system find and remove certain cells. People who join this study will receive the drug through an IV (a tube that goes into a vein) four times over six months. The study lasts for about 48 weeks, and doctors will check participants' health and kidney function regularly.

• Study Length: 48 weeks with scheduled follow-ups.
• Participation: Includes four IV treatments and regular health check-ups.
• Eligibility: Must have PMN with specific health criteria and no recent serious health issues.

This study is seeking about 45 participants. If you have a diagnosis of PMN and meet the health requirements, you might be eligible. Remember, you should not join if you have certain other health conditions or if you are pregnant or breastfeeding.